Details of the Drug Pharmacogenomic Perturbation Atlas

Bethanechol Drug Info

Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium

Therapeutic Class

Parasympathomimetics

Cross-matching ID

PubChem CID

2370

ChEBI ID

CHEMBL1482

CAS Number

CAS 674-38-4

TTD Drug ID

D07ZTO

ACDINA Drug ID

D00066

General Information of Drug (ID: DMCLHO0)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ribosome biogenesis in eukaryotes	1.99	1.22e-2	52/108 (48.15%)	GNL3;FBL;NVL;...
Caffeine metabolism	-1.70	1.82e-2	5/6 (83.33%)	XDH;NAT2;CYP1A2;...
Fructose and mannose metabolism	-1.70	1.83e-2	30/33 (90.91%)	PFKFB2;TIGAR;FPGT;...
Tuberculosis	-1.70	1.89e-2	159/180 (88.33%)	MAPK14;TGFB3;BID;...
C-type lectin receptor signaling pathway	-1.72	1.78e-2	93/104 (89.42%)	NFKBIA;CYLD;ITPR3;...
Fc gamma R-mediated phagocytosis	-1.73	1.68e-2	79/97 (81.44%)	RAC2;MAPK1;PTPRC;...
Fluid shear stress and atherosclerosis	-1.73	1.75e-2	123/139 (88.49%)	CTNNB1;JUN;SUMO4;...
Chagas disease	-1.74	1.70e-2	93/102 (91.18%)	NFKBIA;GNA15;MAPK14;...
Complement and coagulation cascades	-1.74	1.77e-2	76/85 (89.41%)	PLAT;ITGB2;C6;...
Proteoglycans in cancer	-1.75	1.72e-2	172/205 (83.9%)	SDC1;FZD3;RDX;...
Osteoclast differentiation	-1.77	1.53e-2	117/127 (92.13%)	SPI1;LILRA1;FYN;...
Legionellosis	-1.77	1.60e-2	51/57 (89.47%)	CASP9;HSPD1;NAIP;...
Autophagy	-1.78	1.38e-2	113/169 (66.86%)	CTSD;RAB8A;RB1CC1;...
Thyroid hormone signaling pathway	-1.80	1.46e-2	112/121 (92.56%)	SLC16A2;MYH7;NCOA3;...
Proteasome	-1.80	1.54e-2	44/46 (95.65%)	PSMD9;PSMB4;PSMC6;...
Spinocerebellar ataxia	-1.81	1.46e-2	128/143 (89.51%)	PUM1;PIK3R4;GRIN1;...
Staphylococcus aureus infection	-1.81	1.55e-2	72/95 (75.79%)	KRT17;FPR3;FCGR2C;...
Bladder cancer	-1.82	1.46e-2	40/41 (97.56%)	MMP9;MAPK1;MMP1;...
Toxoplasmosis	-1.83	1.57e-2	103/112 (91.96%)	NFKBIA;CASP3;MAPK14;...
Diabetic cardiomyopathy	-1.85	9.72e-3	162/203 (79.8%)	NDUFB2;VDAC3;NCF4;...
AGE-RAGE signaling pathway in diabetic complications	-1.86	1.06e-2	97/100 (97%)	PRKCB;SMAD4;PLCE1;...
Lipid and atherosclerosis	-1.87	8.75e-3	190/215 (88.37%)	LY96;DDIT3;MAP2K7;...
Shigellosis	-1.88	8.10e-3	180/246 (73.17%)	ITGB1;NAIP;PLCE1;...
Leishmaniasis	-1.88	9.11e-3	67/77 (87.01%)	NCF4;MAPK14;TGFB3;...
Phagosome	-1.89	6.25e-3	118/152 (77.63%)	COLEC12;ATP6V0B;ATP6V1B2;...
Systemic lupus erythematosus	-1.93	4.86e-3	45/135 (33.33%)	HLA-DPB1;ACTN4;CTSG;...
Leukocyte transendothelial migration	-1.95	2.92e-3	90/114 (78.95%)	NCF4;MAPK14;GNAI1;...
HIF-1 signaling pathway	-2.00	3.64e-3	105/109 (96.33%)	PFKP;IFNGR2;CDKN1B;...
Pertussis	-2.03	4.86e-3	64/76 (84.21%)	CASP3;C4BPB;MAPK14;...
Neutrophil extracellular trap formation	-2.03	7.29e-3	101/189 (53.44%)	MAPK11;GSDMD;FGB;...
Mineral absorption	-2.10	0.00e+0	48/60 (80%)	ATP1A2;FTL;ATP7A;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	20uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H